GELSOMINO, FRANCESCO
GELSOMINO, FRANCESCO
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE
Collaboratori
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results
2016 G Polverari, V Ambrosini, F Gelsomino, S Diodato, F Ceci, F Sperandi, A Ardizzoni, S Fanti
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event
2018 Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience
2020 Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F.
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding
2018 Dall'Olio, Filippo Gustavo; Sperandi, Francesca; Rihawi, Karim; Gargiulo, Mauro; Melotti, Barbara; Brocchi, Stefano; Gelsomino, Francesco*; Ardizzoni, Andrea
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
2020 Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab
2018 Facchinetti, Francesco*; Veneziani, Michele; Buti, Sebastiano; Gelsomino, Francesco; Squadrilli, Anna; Bordi, Paola; Bersanelli, Melissa; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Mazzaschi, Giulia; Leonardi, Francesco; Quaini, Federico; Ardizzoni, Andrea; Missale, Gabriele; Tiseo, Marcello
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC
2019 Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi, Andrea Ardizzoni
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
2020 Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A.
IFN-γ and CD38 in Hyperprogressive Cancer Development
2021 Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna
Immune-mediated cholangitis: is it always nivolumab’s fault?
2018 Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
2019 Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.; Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A.
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
2020 Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F.
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
2020 Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A.
Next-generation technologies in predictive molecular pathology of lung cancers
2022 de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, Elisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury
2017 Gelsomino, F; Vitale, G.; D'Errico, A.; Bertuzzi, C.; Andreone, P.; Ardizzoni, A.
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report
2020 Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi C.; Brocchi S.; Ardizzoni A.
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence
2017 Rihawi, Karim; Gelsomino, Francesco*; Sperandi, Francesca; Melotti, Barbara; Fiorentino, Michelangelo; Casolari, Laura; Ardizzoni, Andrea
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
2020 Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A.
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice?
2017 Bersanelli M.; Gelsomino F.; Buti S.; Fiorentino M.; Tiseo M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| 18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results | G Polverari, V Ambrosini, F Gelsomino, S Diodato, F Ceci, F Sperandi, A Ardizzoni, S Fanti | 2016-01-01 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | - | 4.02 Riassunto (Abstract) | - |
| A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event | Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea | 2018-01-01 | INVESTIGATIONAL NEW DRUGS | - | 1.01 Articolo in rivista | - |
| Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience | Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F. | 2020-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
| Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding | Dall'Olio, Filippo Gustavo; Sperandi, Francesca; Rihawi, Karim; Gargiulo, Mauro; Melotti, Barbara...; Brocchi, Stefano; Gelsomino, Francesco*; Ardizzoni, Andrea | 2018-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) | Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Man...druzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Gelsomino_CHANCE_TAMO'20.pdf |
| Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma | Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab | Facchinetti, Francesco*; Veneziani, Michele; Buti, Sebastiano; Gelsomino, Francesco; Squadrilli, ...Anna; Bordi, Paola; Bersanelli, Melissa; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Mazzaschi, Giulia; Leonardi, Francesco; Quaini, Federico; Ardizzoni, Andrea; Missale, Gabriele; Tiseo, Marcello | 2018-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC |
Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Bro...cchi, Giuseppe Rossi, Andrea Ardizzoni |
2019-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer | Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A. | 2020-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | Parisi_Cystic airspaces_JIC'20.pdf |
| IFN-γ and CD38 in Hyperprogressive Cancer Development | Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco;... Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | CD38 cancers-13-00309-v2.pdf |
| Immune-mediated cholangitis: is it always nivolumab’s fault? | Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea | 2018-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC | Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.;... Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A. | 2019-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 2019_Immunotherapy.pdf |
| Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance | Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F. | 2020-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | ICI_Targeted_Oncology_2020.pdf; 11523_2020_738_MOESM1_ESM.pdf |
| New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event | Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C....; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Lamberti_atheromatous plaque_TAMO'20.pdf |
| Next-generation technologies in predictive molecular pathology of lung cancers | de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, E...lisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni | 2022-01-01 | Journal of Xiangya Medicine | - | 1.01 Articolo in rivista | 8323-PB5-2020-R3.pdf |
| Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury | Gelsomino, F; Vitale, G.; D'Errico, A.; Bertuzzi, C.; Andreone, P.; Ardizzoni, A. | 2017-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report | Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi ...C.; Brocchi S.; Ardizzoni A. | 2020-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence | Rihawi, Karim; Gelsomino, Francesco*; Sperandi, Francesca; Melotti, Barbara; Fiorentino, Michelan...gelo; Casolari, Laura; Ardizzoni, Andrea | 2017-01-01 | THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE | - | 1.01 Articolo in rivista | 10.1177_1753465817725486.pdf |
| Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) | Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo ...L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A. | 2020-01-01 | BRITISH JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? | Bersanelli M.; Gelsomino F.; Buti S.; Fiorentino M.; Tiseo M. | 2017-01-01 | TRANSLATIONAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |